10x Genomics Q3 Loss Narrows, Revenue Rises; Lifts 2026 Guidance; Shares Fall After Hours

05:23 PM EST, 11/05/2026 (MT Newswires) -- 10x Genomics (TXG) reported a Q3 loss late Thursday of $0.15 per diluted share, narrowing from a loss of $0.22 a year earlier. Analysts polled by FactSet expected a loss of $0.27. Revenue for the quarter ended Sept. 30 was $150.7 million, up from $149.0 million a year earlier. Analysts expected $148.0 million. For full-year 2026, the company now expects revenue of $625 million to $635 million, up from its prior guidance of $610 million to $630 million. Analysts expect $620.8 million. Shares of 10x Genomics were down 12.5% in after-hours trading.